Moderna Secures $1.5B Credit Line & First Revenue Upswing in 3 Years—Turnaround Sparks Investor Confidence
Moderna’s $1.5B credit line and first revenue rise in three years signal a strategic turnaround from its pandemic‑era focus to a diversified, mRNA‑driven growth trajectory.
3 minutes to read









